Amlexanox vs Tesofensine
A side-by-side research comparison of Amlexanox and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Amlexanox | Tesofensine |
|---|---|---|
| Full name | Amlexanox (TBK1/IKKε Inhibitor) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Research / Off-label | Phase 3 Clinical Trial |
| Mechanism | Inhibits IKKε and TBK1 kinases that are upregulated in obesity, which normally suppress energy expenditure. Blocking these kinases restores thermogenesis and improves insulin sensitivity. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 298.29 Da | 329.4 Da |
| Half-life | ~3-4 hours | 8-10 days |
| Bioavailability | ~70% oral | High (oral ~93%) |
| Typical dose | 25-100 mg | 0.25-0.5 mg |
| Frequency | 3x daily | Once daily |
| Route | Oral tablet | Oral |
Amlexanox reported benefits
- Increased energy expenditure
- Improved insulin sensitivity
- Weight loss
- Reduced inflammation
- Metabolic reset
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.